{
    "2020-03-02": [
        [
            {
                "time": "2020-03-18",
                "original_text": "Pfizer identified some antiviral compounds with potential as coronavirus treatments",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "antiviral",
                        "compounds",
                        "coronavirus",
                        "treatments"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-17",
                "original_text": "U.S. Death Toll Rises to Six; Fauci Sees Pandemic: Virus Update",
                "features": {
                    "keywords": [
                        "U.S.",
                        "Death",
                        "Toll",
                        "Fauci",
                        "Pandemic",
                        "Virus"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "public health"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-03-16",
                "original_text": "52-Week Company Lows",
                "features": {
                    "keywords": [
                        "52-Week",
                        "Company",
                        "Lows"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-03-15",
                "original_text": "Genentech, Medivation vets target cancer resistance with Peninsula biotech's planned $86M IPO",
                "features": {
                    "keywords": [
                        "Genentech",
                        "Medivation",
                        "cancer",
                        "resistance",
                        "IPO"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-14",
                "original_text": "Pfizer Stock Tumbled On Lackluster Earnings — Should You Add Shares?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Stock",
                        "Tumbled",
                        "Lackluster",
                        "Earnings"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-03-13",
                "original_text": "Is Pfizer (PFE) Stock a Solid Choice Right Now?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Stock",
                        "Solid",
                        "Choice"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-12",
                "original_text": "Trump to meet with drugmakers as U.S. sees more coronavirus cases",
                "features": {
                    "keywords": [
                        "Trump",
                        "drugmakers",
                        "coronavirus",
                        "cases"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "public health"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-03-11",
                "original_text": "AbbVie Is A Notable Coronavirus Responder — But Is ABBV Stock A Buy?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Coronavirus",
                        "Responder",
                        "ABBV",
                        "Stock"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-10",
                "original_text": "Pfizer Stock Rises 3%",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Stock",
                        "Rises"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-09",
                "original_text": "U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis",
                "features": {
                    "keywords": [
                        "FDA",
                        "Regulatory",
                        "Submission",
                        "Tanezumab",
                        "Chronic",
                        "Pain",
                        "Osteoarthritis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}